Answers are grounded in this paper and cite their sources.
The digitalization of diabetes treatment is rapidly advancing, resulting in greater differentiation between technical treatment systems [ 1 , 8 ]. The terms ‘digital’, ‘connected’ and ‘smart’ are increasingly being used, particularly in the field of insulin pen therapy; however, these terms have been used inconsistently and vaguely without a clear functional differentiation. This lack of conceptual clarity makes it difficult to clinically evaluate and classify them for regulatory purposes in the context of care and reimbursement.
No takes yet. Share an insight, caveat, or question.
Schlüter et al. (2026) studied this question.
Synapse has enriched one related paper. Consider it for comparative context: